文献速递瓣膜外科

经导管主动脉瓣置换术手术量对终末期肾病患者结局的影响

Impact of Transcatheter Aortic Valve Replacement Volume on Outcomes in Patients With End-Stage Renal Disease.
PubMed 文献 · Ann Thorac Surg · 2025-08-27

基于2016至2021年美国全国再入院数据库,纳入411,311例TAVR住院患者,其中7.3%合并终末期肾病(ESRD)。风险调整后,ESRD与更高的院内死亡率(aOR 1.79)和30天再入院率(aOR 1.87)相关,且住院时间和费用增加;高TAVR手术量医院的获益在ESRD患者中未显现。

要点

  • ESRD患者TAVR术后死亡和再入院风险显著增高,需谨慎选择患者。
  • 高手术量医院可降低非ESRD患者死亡和再入院风险,但ESRD患者无此获益。
  • ESRD患者TAVR术后住院时间延长1.3天,费用增加约1.0千美元。

核心结论

  • ESRD患者TAVR术后死亡、资源使用和再入院风险增加,且高手术量中心未能减轻该风险。

研究设计与样本

  • 回顾性队列研究,查询2016至2021年全国再入院数据库,纳入411,311例年龄≥18岁的TAVR住院患者,按ESRD与非ESRD分层。
  • 采用多变量logistic回归和Nelson-Aalen累积风险分析,按医院年手术量四分位数定义低容量和高容量医院。

主要发现

  • ESRD患者占全部TAVR患者的7.3%。
  • 风险调整后,ESRD与更高的院内死亡率相关(aOR 1.79;95%CI 1.59-2.00)。
  • ESRD与更高的30天再入院风险相关(aOR 1.87;95%CI 1.78-1.96)。
  • ESRD与住院时间延长相关(β +1.3天;95%CI 1.1-1.5)及费用增加相关(β +$1.0K;95%CI 0.5K-1.5K)。
  • 高容量医院与非ESRD患者死亡和再入院风险降低相关,而ESRD患者风险在不同容量医院间相似。

临床怎么用

  • 对ESRD患者行TAVR应加强术前选择和优化,以降低死亡和再入院风险。
  • 不能仅凭高手术量中心来推断ESRD患者TAVR预后改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with end-stage renal disease (ESRD) are at increased risk for calcific aortic stenosis. Given limited data on the efficacy of transcatheter aortic valve replacement (TAVR) in this population, the present study examined acute mortality, complications, and 30-day nonelective readmissions in a national cohort of patients with ESRD. METHODS: The 2016 to 2021 National Readmissions Database was queried to identify all TAVR admissions (in patients aged ≥18 years). Patients were stratified into ESRD and non-ESRD cohorts. Primary outcomes included in-hospital mortality and 30-day readmissions, whereas perioperative complications, length of stay, and hospitalization costs were secondarily assessed. Multivariable logistic regression and Nelson-Aalen cumulative hazard analysis were used to evaluate factors associated with mortality and readmissions, stratified by institutional TAVR volume. Low-volume and high-volume hospitals were defined by quartiles of annual procedural volume. RESULTS: Among 411,311 patients undergoing TAVR, 7.3% had ESRD. After risk adjustment, ESRD remained associated with higher mortality (adjusted odds ratio, 1.79; 95% CI, 1.59-2.00) and readmissions (adjusted odds ratio, 1.87; 95% CI, 1.78-1.96). Additionally, ESRD was linked to increased length of stay (β, +1.3 days; 95% CI, 1.1-1.5) and costs (β, +$1.0K; 95% CI, 0.5K-1.5K). After accounting for TAVR volume, non-ESRD was associated with a lower risk of mortality and readmission at high-volume hospitals compared with low-volume hospitals, whereas ESRD was associated with similar risks regardless of institutional volume. CONCLUSIONS: Patients with ESRD are at increased risk for postoperative mortality, hospital resource use, and readmissions. This association was not mitigated at high-TAVR volume centers. Given the increased risk of mortality and readmission, careful patient selection and optimization are crucial for patients with ESRD who are undergoing TAVR.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Aguayo E, Kwon OJ, Won M, et al. Impact of Transcatheter Aortic Valve Replacement Volume on Outcomes in Patients With End-Stage Renal Disease. Ann Thorac Surg. 2025. PMID: 40882909. doi:10.1016/j.athoracsur.2025.08.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。